SARS-CoV2 mRNA疫苗后一过性淋巴细胞性结肠炎
本文首次科学报道了接种辉瑞SARS-CoV2 mRNA疫苗后发生淋巴细胞性结肠炎的病例。患者接种第二剂后24小时内出现液性便、腹痛和恶心,症状持续3个月,发病113天后改善。疫苗不良事件报告系统回顾发现5例第二剂mRNA疫苗后显微镜下结肠炎病例,提示应将其纳入严重持续腹泻的鉴别诊断。
要点
- 接种辉瑞SARS-CoV2 mRNA疫苗第二剂后24小时内出现液性便、腹痛和恶心,症状持续3个月,113天后改善。
- 发病98天后内镜见降结肠和直乙结肠斑片状红斑,黏膜评估示淋巴细胞性结肠炎。
- 疫苗不良事件报告系统回顾发现5例第二剂mRNA疫苗后显微镜下结肠炎病例。
核心结论
- 本报告和疫苗不良事件报告系统病例提示,对于SARS-CoV2 mRNA疫苗接种后出现严重、持续性腹泻的患者,提供者应考虑将显微镜下结肠炎纳入鉴别诊断。
研究设计与样本
- 本文为病例报告,报告一例辉瑞SARS-CoV2 mRNA疫苗后淋巴细胞性结肠炎,并回顾疫苗不良事件报告系统数据。
主要发现
- 患者接种第二剂辉瑞SARS-CoV2 mRNA疫苗后24小时内出现液性便、腹痛和恶心,症状持续3个月,发病113天后改善。
- 实验室检查和胃肠道聚合酶链反应正常;发病98天后食管胃十二指肠镜和结肠镜见降结肠和直乙结肠斑片状红斑,黏膜评估示淋巴细胞性结肠炎。
- 疫苗不良事件报告系统回顾发现5例第二剂mRNA疫苗后显微镜下结肠炎病例。
临床怎么用
- 作者认为,对于SARS-CoV2 mRNA疫苗接种后出现严重、持续性腹泻的患者,提供者可考虑将显微镜下结肠炎纳入鉴别诊断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This is the first scientific report describing lymphocytic colitis after administration of the Pfizer severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) messenger RNA (mRNA) vaccine. The patient developed liquid stools, abdominal pain, and nausea within 24 hours of receiving the second dose. Symptoms were persistent for 3 months but improved 113 days after onset. Laboratory profiles and gastrointestinal polymerase chain reaction were normal. Esophagogastroduodenoscopy and colonoscopy performed 98 days after onset revealed patchy erythema in the descending colon and rectosigmoid. Mucosal evaluation revealed lymphocytic colitis. Review of the Vaccine Adverse Event Reporting System revealed 5 cases of microscopic colitis after the second mRNA dose. This report and Vaccine Adverse Event Reporting System cases suggest providers should consider microscopic colitis in the differential diagnosis of patients with severe, persistent diarrhea after the SARS-CoV2 mRNA vaccine.
引用
- Chey SW, Westerhoff M, Chey WD, et al. Transient Lymphocytic Colitis After SARS-CoV2 mRNA Vaccine. Am J Gastroenterol. 2022. PMID: 35130188. doi:10.14309/ajg.0000000000001673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。